Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX10 (DDX10) is an enzyme belonging to the DEAD-box RNA helicase family, characterized by conserved motifs that mediate ATP-dependent RNA unwinding and remodeling[5]. It is crucial for cellular and stem cell homeostasis, ribosome biogenesis, and RNA metabolic processes, including ribosomal RNA (rRNA) processing, particularly the maturation of 18S rRNA and assembly of the small ribosomal subunit[1]. DDX10 localizes predominantly to the nucleolar dense fibrillar and granular components, where it binds and regulates 45S rRNA. Degradation or dysfunction of DDX10, as seen in disease states or via NUP98-DDX10 fusion in cancers, impairs ribosome biogenesis and protein synthesis, leading to cell cycle arrest and apoptosis[1][3]. DDX10 is also involved in liquid-liquid phase separation (LLPS), essential for formation of nucleolar structures and efficient ribosome production[1]. Dysregulation or fusion involving DDX10 contributes to leukemogenesis and is associated with abnormal expression in various solid tumors, modulating cell proliferation and tumorigenic signaling pathways[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX10 (DDX10).